← The Wire
CRNXNasdaq
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations · DE · CIK 1658247
Crinetics Pharmaceuticals discovers, develops, and commercializes novel therapies for endocrine diseases and tumors
red 8-K · 90d
$3.63B
Market cap
$36.94
Last close
+0.7%
1D
+4.4%
5D
884K
Volume
Price · last 39 sessions-10.4%
May 4L $32.61 · H $43.49Jun 29
201
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 22, 20268-KResults of OperationsMay 7, 20268-KExecutive ChangeApr 10, 20268-KExecutive ChangeMar 23, 20268-KAuditor ChangeMar 3, 20268-KResults of OperationsFeb 26, 20268-KExecutive ChangeJan 26, 20268-KResults of Operations · Reg FD DisclosureJan 13, 20268-KCompany UpdateJan 7, 20268-KResults of Operations · Reg FD DisclosureJan 5, 20268-KExecutive ChangeDec 17, 20258-KResults of OperationsNov 6, 20258-KReg FD Disclosure · Company UpdateSep 26, 20258-KResults of OperationsAug 7, 20258-KReg FD DisclosureJun 30, 20258-KReg FD Disclosure · Company UpdateJun 26, 20258-KShareholder VoteJun 12, 20258-KResults of OperationsMay 8, 20258-KExecutive ChangeApr 4, 20258-KResults of OperationsFeb 27, 20258-KExecutive Change · Reg FD DisclosureFeb 24, 20258-KReg FD DisclosureJan 14, 20258-KReg FD Disclosure · Company UpdateJan 10, 20258-KExecutive Change · Reg FD DisclosureDec 16, 20248-KCompany UpdateDec 9, 20248-KResults of OperationsNov 12, 20248-KExecutive ChangeOct 16, 20248-KCompany UpdateOct 9, 20248-KCompany UpdateSep 26, 20248-KExecutive ChangeSep 17, 20248-KResults of OperationsAug 8, 20248-KCompany UpdateJun 21, 20248-KShareholder VoteJun 10, 20248-KReg FD Disclosure · Company UpdateJun 3, 20248-KReg FD DisclosureMay 22, 20248-KResults of OperationsMay 9, 20248-KReg FD DisclosureMay 8, 20248-KExecutive ChangeApr 4, 20248-KReg FD Disclosure · Company UpdateMar 19, 20248-KReg FD Disclosure · Company UpdateMar 12, 20248-KMaterial Agreement · Equity IssuanceMar 1, 20248-KResults of OperationsFeb 28, 20248-KReg FD DisclosureJan 8, 20248-KReg FD Disclosure · Company UpdateDec 18, 20238-KBylaw AmendmentDec 12, 20238-KResults of OperationsNov 7, 20238-KCompany UpdateSep 13, 20238-KReg FD Disclosure · Company UpdateSep 11, 20238-KResults of OperationsAug 8, 20238-KShareholder VoteJun 21, 20238-KResults of OperationsMay 4, 20238-KCompany UpdateMar 13, 20238-KResults of OperationsFeb 28, 20238-KReg FD DisclosureJan 9, 20238-KCompany UpdateNov 28, 20228-KResults of OperationsNov 14, 20228-KCompany UpdateOct 13, 20228-KExecutive ChangeOct 3, 20228-KMaterial Agreement · New Debt / ObligationSep 15, 20228-KResults of OperationsAug 12, 20228-KShareholder VoteJun 21, 20228-KReg FD Disclosure · Company UpdateMay 25, 20228-KResults of OperationsMay 12, 20228-KCompany UpdateApr 13, 20228-KResults of Operations · Reg FD DisclosureMar 30, 20228-KExecutive ChangeMar 25, 20228-KCompany UpdateMar 18, 20228-KExecutive ChangeMar 14, 20228-KExecutive ChangeMar 1, 20228-KMaterial AgreementFeb 28, 20228-KCompany UpdateJan 12, 20228-KExecutive ChangeJan 5, 20228-KExecutive ChangeDec 23, 20218-KCompany UpdateNov 8, 20218-KResults of OperationsNov 5, 20218-KCompany UpdateOct 21, 20218-KResults of OperationsOct 20, 20218-KCompany UpdateOct 18, 20218-KCompany UpdateSep 27, 20218-KReg FD Disclosure · Company UpdateSep 15, 2021
Insider Activity
In the 90 days to Mar 16, 2026: 7 sold $2.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Struthers Richard ScottPresident & CEO | Sell | 13,196 | $37.11 | $490K |
| Mar 16, 2026 | Struthers Richard ScottPresident & CEO | Sell | 8,785 | $37.77 | $332K |
| Mar 16, 2026 | Betz Stephen F.Chief Scientific Officer | Sell | 6,371 | $37.11 | $236K |
| Mar 16, 2026 | Knight Jeff E.Chief Operating Officer | Sell | 5,950 | $37.11 | $221K |
| Mar 16, 2026 | Betz Stephen F.Chief Scientific Officer | Sell | 4,241 | $37.77 | $160K |
| Mar 16, 2026 | Knight Jeff E.Chief Operating Officer | Sell | 3,961 | $37.77 | $150K |
| Mar 12, 2026 | Vivaldi Coelho RogerioDirector | Sell | 4,477 | $36.08 | $162K |
| Mar 12, 2026 | Vivaldi Coelho RogerioDirector | Sell | 523 | $36.77 | $19K |
| Mar 3, 2026 | Schilke TobinChief Financial Officer | Sell | 6,713 | $39.67 | $266K |
| Mar 3, 2026 | Okey StephanieDirector | Sell | 3,000 | $39.67 | $119K |
| Jan 5, 2026 | Kalofonos IsabelChief Commercial Officer | Sell | 2,500 | $55.00 | $138K |
| Dec 1, 2025 | Pizzuti DanaChief Med and Dev Officer | Sell | 5,000 | $45.02 | $225K |
| Nov 3, 2025 | Pizzuti DanaChief Med and Dev Officer | Sell | 4,900 | $42.65 | $209K |
| Nov 3, 2025 | Pizzuti DanaChief Med and Dev Officer | Sell | 100 | $43.27 | $4K |
| Oct 1, 2025 | Pizzuti DanaChief Med and Dev Officer | Sell | 5,000 | $41.81 | $209K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance